77359-11-6

Basic information

• Product Name: 4-Nitrobenzyl hydrogen malonate
• Synonyms: MALONIC ACID MONO-4-NITROBENZYL ESTER;MONO P-NITRO BENZYL MALONATE;MONO-4-NITROBENZYL MALONATE;Malonicacidmononitrobenzylester;MALONIC ACID MONO-4-NITROBENZYL ESTER 98+%;4-nitrobenzyl hydrogen malonate;4-NITROBENZYLMALONATE;MONO-4-NITROBENZYLMALONICACIDESTER
• CAS NO: 77359-11-6
• Molecular Formula: C₁₀H₉NO₆
• Molecular Weight: 239.18
• Product Categories: pharmaceutical intermediates
• Mol File: 77359-11-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 109 °C
• Boiling Point: 455.8 °C at 760 mmHg
• Flash Point: 229.5 °C
• Appearance: white to slight yellow powder
• Density: 1.447 g/cm³
• Vapor Pressure: 4.22E-09mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 2.49±0.32(Predicted)
• CAS DataBase Reference: 4-Nitrobenzyl hydrogen malonate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Nitrobenzyl hydrogen malonate(77359-11-6)
• EPA Substance Registry System: 4-Nitrobenzyl hydrogen malonate(77359-11-6)

Safety Data

• Hazardous Substances Data: 77359-11-6(Hazardous Substances Data)

Usage

Uses

4-Nitrobenzyl hydrogen malonate is a reagent used in the synthesis of (±)-thienamycin, a β-Lactam antibiotics. Also, it is useful for chiral key intermediate of carbapenem syntheses.

InChI:InChI=1/C10H9NO6/c12-9(13)5-10(14)17-6-7-1-3-8(4-2-7)11(15)16/h1-4H,5-6H2,(H,12,13)

Upstream product

• 67245-85-6 Bis(p-nitrobenzyl) malonate 
• 2033-24-1 cycl-isopropylidene malonate 
• 619-73-8 4-nitrobenzyl chloride 
• 28509-24-2 tert-butylmethyl ether 
• 71001-49-5 4-nitrobenzyl-2-cyanoacetate 
• 100-14-1 4-nitrobenzyl chloride 
• 100-11-8 1-bromomethyl-4-nitro-benzene 
• 141-82-2 malonic acid 

Downstream Products

• 117679-86-4 p-Nitrobenzyl ester of N-Methyl-N-(benzyloxy)malonamide 
• 93711-81-0 (4-nitrophenyl)methyl (4R,5R,6S)-3-[(diphenoxyphosphinyl)oxy]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate 
• 105995-50-4 magnesium 4-nitrobenzyl malonate 
• 75321-07-2 (3S,4R)-3-[(R)-1-hydroxyethyl]-4-[3-(4-nitrobenzyl)-oxycarbonyl-2-oxopropyl]azetidin-2-one 
• 109323-64-0 (3S,4S)-3-(1R-tert-butyldimethylsiloxyethyl)-4-(p-nitrobenzyloxycarbonyldiazoacetoamino)methylazetidin-2-one 

Relevant articles and documents

Preparation method of nitrobenzyl hydrogen malonate

The invention relates to a preparation method of nitrobenzyl hydrogen malonate. Particularly, the preparation method comprises the steps of taking a compound shown as formula I and a compound shown asformula II as starting materials, performing esterification reaction to form an intermediate compound shown as formula III, and performing hydrolysis reaction on the compound shown as formula III toform nitrobenzyl hydrogen malonate (a compound shown as formula IV). The preparation method has the advantages of simplicity in operation, low cost, greenness, cleanness and the like and is suitable for industrial production.

Syntheses and evaluation of substituted aromatic hydroxamates and hydroxamic acids that target Mycobacterium tuberculosis

Tuberculosis (TB) continues to remain one of the most threatening diseases in the world. With the emergence of multi-drug resistant (MDR) and extensively drug resistant (XDR) strains, the need to develop new therapies is dire. The syntheses of a focused library of hydroxamates and hydroxamic acids is described, as well as anti-TB activity in the microplate alamar blue assay (MABA). A number of compounds exhibited good activity against Mtb, with notable compounds exhibiting MIC values in the range of 20-0.71 μM. This work suggests that both hydroxamates and their free acids may be incorporated into more complex scaffolds and serve as potential leads for the development of anti-TB agents.

Synthesis of bone-targeted oestrogenic compounds for the inhibition of bone resorption

Syntheses have been realised for several members of a new class of potential bone resorption inhibitors consisting of steroidal oestrogenic compounds linked at the 17 position to a geminal bis(phosphonic acid) moiety through an ester linkage. The approach used has the potential to allow other biologically active compounds to be coupled to the geminal bisphosphonate unit.